Primary myelofibrosis: own experience and news from diagnostic and treatment

Cover Page

Cite item

Full Text

Abstract

The newest advances in primary myelofibrosis (PMF) pathogenesis study, diagnostic and treatment approaches are presented in this article. The JAK-STAT signal pathway activation now recognized as main pathogenesis mechanism of PMF, it caused by JAK2, CALR, MPL genes mutations. Authors demonstrate their own data about epidemiology, clinical signs, diagnostic and treatment results of 315 PMF patients. The most frequent clinical symptoms are: anemia, leukocytosis, thrombocytosis, splenomegaly, constitutional symptoms. Diagnostic criteria, prognostic scales (including cytogenetic and molecular features) issues are reviewed. Intermediate-1 risk grade is in the most proportion of patients. The
recommended PMF treatment algorithm is listed. The treatment methods, target drugs (Janus kinases inhibitors) trials results are discussed.

About the authors

K. M. Abdulkadyrov

Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency; 16, 2 nd Sovetskaya St., St. Petersburg, 191024, Russia

Russian Federation

V. A. Shuvaev

Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency; 16, 2 nd Sovetskaya St., St. Petersburg, 191024, Russia

Author for correspondence.
Email: shuvaev77@mail.ru
Russian Federation

I. S. Martynkevich

Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency; 16, 2 nd Sovetskaya St., St. Petersburg, 191024, Russia

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.